Thrombin generation and its inhibition: A review of the scientific basis and mechanism of action of anticoagulant therapies

British Journal of Anaesthesia

Volumn 88, Issue 6, 2002, Pages 848-863

  Walker, C P R ^a   Royston, D ^a  

^a HAREFIELD HOSPITAL   (United Kingdom)

Author keywords

Blood, anticoagulants; Blood, coagulation

Indexed keywords

ABCIXIMAB; ACENOCOUMAROL; ACETYLSALICYLIC ACID; ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; ANTITHROMBIN; ANTIVITAMIN K; CLOPIDOGREL; DALTEPARIN; DESULFATOHIRUDIN; DIAZEPAM; DICOUMAROL; ENDOTHELIUM DERIVED CONSTRICTING FACTOR; ENOXAPARIN; HEPARIN; HIRUDIN; HIRULOG; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PHENPROCOUMON; PROPRANOLOL; PROTAMINE SULFATE; SELAPARIN; SERINE PROTEINASE INHIBITOR; THROMBIN; THROMBOPLASTIN; TICLOPIDINE; TISSUE FACTOR PATHWAY INHIBITOR; UNINDEXED DRUG; WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DEGRADATION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG UPTAKE; HEART ATRIUM FIBRILLATION; HUMAN; LUNG EMBOLISM; PRIORITY JOURNAL; REVIEW; VEIN THROMBOSIS;

EID: 0036270049     PISSN: 00070912     EISSN: None     Source Type: Journal    
DOI: 10.1093/bja/88.6.848     Document Type: Review

References (85)

1. Guidelines on oral anticoagulation: Third edition
2. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: A randomised trial
3. Antithrombosis routines and hemorrhagic complications: A seven year survey comparing vascular and general surgical operations
4. Mutation in blood coagulation factor V associated with resistance to activated protein C
5. Mechanism of the anticoagulant action of heparin
6. Heparin kinetics determined by three assay methods
7. Substitution of antithrombin III in shock and DIC: A randomized study
8. Pharmacokinetics of full length and two-domain tissue factor pathway inhibitor in combination with heparin in rabbits
9. Establishing a therapeutic range for heparin therapy
10. Thromboembolic disease due to thermolabile conformational changes of antithrombin Rouen-VI (187 Asn→Asp)
11. Factor VIII and DDAVP reverse the effect of recombinant desulphatohirudin (CGP 39393) on bleeding in the rat
12. Anticoagulation of pregnant women with mechanical heart valves: A systematic review of the literature
13. Heparin-induced thrombocytopenia
14. Metabolism of antithrombin III (heparin cofactor) in man: Effects of venous thrombosis and of heparin administration
15. Drug treatment associated with heart valve replacement
16. Antithrombin III Geneva: A hereditary abnormal ATIII with defective heparin cofactor activity
17. Kinetics of intravenously administered heparin in normal humans
18. The impact of heparin concentration and activated clotting time monitoring on blood conservation. A prospective, randomized evaluation in patients undergoing cardiac operation
19. Inhibitors of the platelet receptor glycoprotein IIb-IIIa and complications during percutaneous coronary revascularization. Management strategies for the cardiac surgeon
20. Immediate coronary artery bypass surgery after platelet inhibition with eptifibatide: Results from PURSUIT. Platelet glycoprotein IIb/IIIa in unstable angina: Receptor suppression using integrelin therapy
21. Pharmacology of the low-molecular-weight heparins
22. Comparative study on the in vitro and in vivo activities of seven low-molecular-weight heparins
23. Some objective considerations for the neutralization of the anticoagulant actions of recombinant hirudin
24. Double-blind, placebo-controlled trial of antithrombin III concentrates in septic shock with disseminated intravascular coagulation
25. Thrombin activity of fibrin thrombi and soluble plasmic derivatives
26. Low-molecular-weight heparins: An overview of their pharmacodynamics, pharmacokinetics and metabolism in humans
27. Heparinase-1 vs. protamine for heparin neutralization after bypass
28. Inhibitory properties of full-length and truncated recombinant tissue factor pathway inhibitor (TFPI). Evidence that the third Kunitz-type domain of TFPI is not essential for the inhibition of factor VIIa-tissue cell surfaces
29. Heparin
30. Oral anticoagulant drugs
31. Heparin: Mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety
32. Low molecular weight heparin
33. Low molecular weight heparin: Laboratory properties and clinical evaluation. A review
34. Anticoagulation and neuraxial block: Historical perspective, anesthetic implications, and risk management
35. Pharmacokinetics of a very low molecular weight heparin in chronic renal failure
36. Immunologic response to recombinant hirudin in HIT type II patients during long-term treatment
37. Low molecular weight heparin treatment of venous thromboembolism
38. Protein C response to induction of warfarin treatment after coronary bypass operation
39. Increased accuracy and precision of heparin and protamine dosing reduces blood loss and transfusion in patients undergoing primary cardiac operations
40. Efficacy and safety of a low-molecular-weight heparin and standard unfractionated heparin for prophylaxis of postoperative venous thromboembolism: European multicenter trial
41. Effect of thrombin inhibition in vascular dementia and silent cerebrovascular disease. An MR spectroscopy study
42. Bleeding after intermittent or continous r-hirudin during CVVH
43. Effect of the thrombin inhibitor argatroban in acute cerebral thrombosis
44. Coagulation/ fibrinolysis disorder in patients with severe preeclampsia
45. Anticoagulant-related bleeding: Clinical epidemiology, prediction, and prevention
46. Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4
47. Treatment of heparin-associated thrombocytopenia and thrombosis with low molecular weight heparin (CY 216)
48. Current concepts in anticoagulant therapy
49. The binding of thrombin by fibrin
50. Epidural anesthesia and analgesia: Their role in postoperative outcome
51. Recombinant hirudin anticoagulation for aortic valve replacement in heparin-induced thrombocytopenia
52. Structure of a dermatan sulfate hexasaccharide that binds to heparin cofactor II with high affinity
53. Anticoagulantly active heparin-like molecules from vascular tissue
54. Coagulation/fibrinolysis balance in septic shock related to cytokines and clinical state
55. Melagatran, an oral active-site inhibitor of thrombin, prevents or delays formation of electrically induced occlusive thrombus in the canine coronary artery
56. Nonfatty acid-modulated variations in drug binding due to heparin
57. Coagulation and fibrinolytic studies during pregnancy
58. Clinical experience of argatroban for anticoagulation in cardiovascular surgery
59. Predominant contribution of surface approximation to the mechanism of heparin acceleration of the antithrombin-thrombin reaction. Elucidation from salt concentration effects
60. Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement
61. Binding of high affinity heparin to antithrombin III. Stopped flow kinetic studies of the binding interaction
62. Heparin binding defect in a new antithrombin III variant: Rouen, 47 Arg to His
63. Monitoring of recombinant hirudin: Assessment of a plasma-based ecarin clotting time assay
64. Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass-assessment of the whole blood ecarin clotting time
65. Regulation of the tissue factor pathway
66. Factor V Leiden (resistance to activated protein C) increases the risk of myocardial infarction in young women
67. Simple and safe method to prepare patients with prosthetic heart valves for surgical dental procedures
68. Effect of heparin and heparin fractions on platelet aggregation
69. Small, noncovalent serine protease inhibitors
70. Efficacious, orally bioavailable thrombin inhibitors based on 3-aminopyridinone or 3-aminopyrazinone acetamide peptidomimetic templates
71. Treatment of coumarin-induced skin necrosis with a monoclonal antibody purified protein C concentrate
72. Kinetics of heparin action
73. Skin necrosis and protein C deficiency associated with vitamin K depletion in a patient with renal failure
74. The pharmacokinetics and pharmacodynamics of argatroban: Effects of age, gender, and hepatic or renal dysfunction
75. Effects of heparin oligosaccharides with high affinity for antithrombin III in experimental venous thrombosis
76. Heparin cofactor II. Purification and properties of a heparin-dependent inhibitor of thrombin in human plasma
77. Argatroban increases nitric oxide levels in patients with peripheral arterial obstructive disease: Placebo-controlled study
78. Anticoagulants and spinal-epidural anesthesia
79. Myths of dental surgery in patients receiving anticoagulant therapy
80. Heparin-induced thrombocytopenia: A ten-year retrospective
81. Heparin-induced thrombocytopenia
82. Low-molecular-weight heparins
83. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors
84. Relationship between concentration and anticoagulant effect of heparin in plasma of hospitalized patients: Magnitude and predictability of interindividual differences
85. Antithrombin, prekallikrein, and fibronectin levels in surgical patients